注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Renalytix plc是一家依託人工智能技術的體外診斷公司。該公司專注於優化腎臟疾病的臨床管理,以改善患者預後情況,推動價值性護理。該公司的診斷平台KidneyIntelX旨在擴展糖尿病腎病以外的腎病狀況。該公司正在評估慢性腎病、心腎病、不同人群的慢性腎病和冠狀病毒病(COVID)相關腎病的一系列新適應症。KidneyIntelX平台通過結合各種數據輸入促進數據識別,對面臨早期糖尿病腎病(DKD)風險的患者進行有效管理,其數據輸入包括包括經過驗證的基於血液的生物標誌物、遺傳基因和來自電子健康記錄(HER)的個性化患者數據,再利用專有算法生成獨特的患者風險評分。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Christopher Harwood-Bernard Mills | 71 | 2018 | Independent Non-Executive Chairman |
Daniel Joseph Levangie | 73 | 2021 | Independent Non-Executive Director |
Erik K. Lium | 56 | 2018 | Independent Non-Executive Director |
Catherine Coste | 57 | 2023 | Independent Non-Executive Director |
Eugene E. Wright | - | 2023 | Member of Clinical Advisory Board |
Joseph A. Vassalotti | - | 2019 | Member of Clinical Advisory Board |
Barry I. Freedman | - | - | Member of Clinical Advisory Board |
Matthew Jay Budoff | - | 2023 | Member of Clinical Advisory Board |
Javier Morales | - | 2023 | Member of Clinical Advisory Board |
Stephen Brunton | - | 2023 | Member of Clinical Advisory Board |
Ralph A. Defronzo | - | 2023 | Member of Clinical Advisory Board |
Holly J. Mattix-Kramer | - | 2023 | Member of Clinical Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核